Associations of various gene polymorphisms with toxicity in colorectal cancer patients receiving oral uracil and tegafur plus leucovorin: A prospective study

Annals of Oncology

Volumn 22, Issue 2, 2011, Pages 355-361

  Tsunoda, A ^a   Nakao, K ^b   Watanabe, M ^b   Matsui, N ^b   Ooyama, A ^c   Kusano, M ^b  

^a KAMEDA MEDICAL CENTER   (Japan)

^b SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

5 fluorouracil; Orotate phosphoribosyltransferase; Polymorphism; Tegafur uracil; Toxicity

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CYTOCHROME P450 2A6; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; FOLINIC ACID; GLUCURONOSYLTRANSFERASE 1A1; HISTAMINE H2 RECEPTOR ANTAGONIST; LAFUTIDINE; METHYLENETETRAHYDROFOLATE HOMOCYSTEINE METHYLTRANSFERASE; METHYLENETETRAHYDROFOLIC ACID; OROTATE PHOSPHORIBOSYLTRANSFERASE; REDUCED FOLATE CARRIER; THYMIDYLATE SYNTHASE; UFT; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER STAGING; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DNA POLYMORPHISM; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLATE METABOLISM; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HYPERBILIRUBINEMIA; LEUKOPENIA; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; PIGMENT DISORDER; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SMELLING DISORDER; STOMATITIS; TASTE DISORDER; THROMBOCYTOPENIA; UNTRANSLATED REGION; VOMITING;

EID: 79251549824     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq358     Document Type: Article

References (43)

1. Lamont EB, Schilsky RL. The oral fluoropyrimidines in cancer chemotherapy. Clin Cancer Res 1999; 5: 2289-2296.
2. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005; 352: 476-487.
3. Rich TA, Shepard RC, Mosley ST. Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy. J Clin Oncol 2004; 22: 2214-2232.
4. Fujii S, Kitano S, Ikenaka K, Shirasaka T. Effect of coadministration of uracil or cytosine on the anti-tumor activity of clinical doses of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents. Gann 1979; 70: 209-214.
5. Lembersky BC, Wieand HS, Petrelli NJ et al. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 2006; 24: 2059-2064.
6. Kopec JA, Yothers G, Ganz PA et al. Quality of life in operable colon cancer patients receiving oral compared with intravenous chemotherapy: results from National Surgical Adjuvant Breast and Bowel Project Trial C-06. J Clin Oncol 2007; 25: 424-430.
7. Nakajima M, Kwon JT, Tanaka N et al. Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans. Clin Pharmacol Ther 2001; 69: 72-78.
8. Kawakami K, Graziano F, Watanabe G et al. Prognostic role of thymidylate synthase polymorphisms in gastric cancer patients treated with surgery and adjuvant chemotherapy. Clin Cancer Res 2005; 11: 3778-3783.
9. Kumagai K, Hiyama K, Oyama T et al. Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis. Int J Mol Med 2003; 11: 593-600.
10. Harmon DL, Shields DC, Woodside JV et al. Methionine synthase D919G polymorphism is a significant but modest determinant of circulating homocysteine concentrations. Genet Epidemiol 1999; 17: 298-309.
11. Chango A, Emery-Fillon N, de Courcy GP et al. A polymorphism (80G->A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia. Mol Genet Metab 2000; 70: 310-315.
12. Sai K, Saeki M, Saito Y et al. UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin Pharmacol Ther 2004; 75: 501-515.
13. Vasconcelos GM, Struchiner CJ, Suarez-Kurtz G. CYP2A6 genetic polymorphisms and correlation with smoking status in Brazilians. Pharmacogenomics J 2005; 5: 42-48.
14. Daigo S, Takahashi Y, Fujieda M et al. A novel mutant allele of the CYP2A6 gene (CYP2A6*11) found in a cancer patient who showed poor metabolic phenotype towards tegafur. Pharmacogenetics 2002; 12: 299-306.
15. Xu C, Rao YS, Xu B et al. An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles. Biochem Biophys Res Commun 2002; 290: 318-324.
16. Ichikawa W, Takahashi T, Suto K et al. Orotate phosphoribosyltransferase gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimen. Clin Cancer Res 2006; 12: 3928-3934.
17. Houghton JA, Houghton PJ, Wooten RS. Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine, and 5-fluoro-2'-deoxyuridine. Cancer Res 1979; 39: 2406-2413.
18. Pullarkat ST, Stoehlmacher J, Ghaderi V et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 2001; 1: 65-70.
19. Cohen V, Panet-Raymond V, Sabbaghian N et al. Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clin Cancer Res 2003; 9: 1611-1615.
20. Jakobsen A, Nielsen JN, Gyldenkerne N, Lindeberg J. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J Clin Oncol 2005; 23: 1365-1369.
21. Lecomte T, Ferraz JM, Zinzindohoue F et al. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin Cancer Res 2004; 10: 5880-5888.
22. Sharma R, Hoskins JM, Rivory LP et al. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients. Clin Cancer Res 2008; 14: 817-825.
23. Chen J, Hunter DJ, Stampfer MJ et al. Polymorphism in the thymidylate synthase promoter enhancer region modifies the risk and survival of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2003; 12: 958-962.
24. Diasio RB, Lu Z. Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy. J Clin Oncol 1994; 12: 2239-2242.
25. Diasio RB, Beavers TL, Carpenter JT. Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 1988; 81: 47-51.
26. van Kuilenburg AB, Muller EW, Haasjes J et al. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency. Clin Cancer Res 2001; 7: 1149-1153.
27. Yamaguchi K, Arai Y, Kanda Y, Akagi K. Germline mutation of dihydropyrimidine dehydrogenese gene among a Japanese population in relation to toxicity to 5-fluorouracil. Jpn J Cancer Res 2001; 92: 337-342.
28. Collie-Duguid ES, Etienne MC, Milano G, McLeod HL. Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics 2000; 10: 217-223.
29. Ridge SA, Sludden J, Brown O et al. Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects. Br J Clin Pharmacol 1998; 46: 151-156.
30. Zhang H, Li YM, Jin X. DPYD*5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU: results from genotyping study on 75 gastric carcinoma and colon carcinoma patients. Med Oncol 2007; 24: 251-258.
31. Peters GJ, Laurensse E, Leyva A et al. Sensitivity of human, murine, and rat cells to 5-fluorouracil and 5'-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes. Cancer Res 1986; 46: 20-28.
32. Schwab M, Zanger UM, Marx C et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol 2008; 26: 2131-2138.
33. Capitain O, Boisdron-Celle M, Poirier AL et al. The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer. Pharmacogenomics J 2008; 8: 256-267.
34. Gaughan DJ, Kluijtmans LA, Barbaux S et al. The methionine synthase reductase (MTRR) A66G polymorphism is a novel genetic determinant of plasma homocysteine concentrations. Atherosclerosis 2001; 157: 451-456.
35. Niyikiza C, Baker SD, Seitz DE et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 2002; 1: 545-552.
36. Kawata S, Minami Y, Tarui S et al. Cytochrome P-450-dependent oxidative cleavage of 1-(tetrahydro-2-furanyl)-5-fluorouracil to 5-fluorouracil. Jpn J Pharmacol 1984; 36: 43-49.
37. Minami H, Sai K, Saeki M et al. Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet Genomics 2007; 17: 497-504.
38. Sai K, Saito Y, Sakamoto H et al. Importance of UDP-glucuronosyltransferase 1A1*6 for irinotecan toxicities in Japanese cancer patients. Cancer Lett 2008; 261: 165-171.
39. Araki K, Fujita K, Ando Y et al. Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer. Cancer Sci 2006; 97: 1255-1259.
40. Danoff TM, Campbell DA, McCarthy LC et al. A Gilbert's syndrome UGT1A1 variant confers susceptibility to tranilast-induced hyperbilirubinemia. Pharmacogenomics J 2004; 4: 49-53.
41. Bosma PJ, Chowdhury JR, Bakker C et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 1995; 333: 1171-1175.
42. Aono S, Adachi Y, Uyama E et al. Analysis of genes for bilirubin UDP-glucuronosyltransferase in Gilbert's syndrome. Lancet 1995; 345: 958-959.
43. Alberts DS, Peng YM, Bowden GT et al. Pharmacology of mitoxantrone: mode of action and pharmacokinetics. Invest New Drugs 1985; 3: 101-107.